1. Dementia, psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion of the principle investigator, would affect subject safety and/or compliance. 2. Contraindication to transfusion or history of prior reactions to transfusion blood products. 3. Patients with known selective IgA deficiency. 4. Patients with mechanical ventilation and/or extracoporal membrane oxygenation (ECMO) at time of initial inclusion into the trial. 5. Participation in another trial with an investigational medicinal product. 6. Treatment with SARS-CoV-2 convalescent plasma in the past.

1. Dementia, psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion of the principle investigator, would affect subject safety and/or compliance. 2. Contraindication to transfusion or history of prior reactions to transfusion blood products. 3. Patients with known selective IgA deficiency. 4. Patients with mechanical ventilation and/or extracoporal membrane oxygenation (ECMO) at time of initial inclusion into the trial. 5. Participation in another trial with an investigational medicinal product. 6. Treatment with SARS-CoV-2 convalescent plasma in the past.

1. Dementia, psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion of the principle investigator, would affect subject safety and/or compliance. 2. Contraindication to transfusion or history of prior reactions to transfusion blood products. 3. Patients with known selective IgA deficiency. 4. Patients with mechanical ventilation and/or extracoporal membrane oxygenation (ECMO) at time of initial inclusion into the trial.

1. Dementia, psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion of the principle investigator, would affect subject safety and/or compliance. 2. Contraindication to transfusion or history of prior reactions to transfusion blood products. 3. Patients with known selective IgA deficiency. 4. Patients with mechanical ventilation and/or extracoporal membrane oxygenation (ECMO) at time of initial inclusion into the trial.